Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:available_on |
generic medication
|
| gptkbp:casnumber |
113-24-6
|
| gptkbp:chemical_formula |
C16 H20 N2 O2
|
| gptkbp:composed_by |
venlafaxine metabolism
|
| gptkbp:contraindication |
patients with uncontrolled hypertension
patients with hypersensitivity to venlafaxine |
| gptkbp:developed_by |
gptkb:venlafaxine
|
| gptkbp:excretion |
urine
feces |
| gptkbp:has_impact_on |
serotonin reuptake inhibitor
norepinephrine reuptake inhibitor |
| https://www.w3.org/2000/01/rdf-schema#label |
O-desmethylvenlafaxine
|
| gptkbp:ingredients |
social anxiety disorder
generalized anxiety disorder panic disorder |
| gptkbp:is_a |
gptkb:depression
|
| gptkbp:is_metabolite_of |
gptkb:venlafaxine
|
| gptkbp:is_noted_for |
may interact with other medications
can cause dose-dependent increases in blood pressure improving quality of life in patients lower risk of sexual side effects may require dose adjustment in renal impairment potential for abuse is low fewer withdrawal symptoms compared to other antidepressants |
| gptkbp:is_part_of |
SNRI class of medications
venlafaxine pharmacotherapy venlafaxine treatment regimen |
| gptkbp:is_regulated_by |
gptkb:FDA
|
| gptkbp:is_related_to |
serotonin-norepinephrine reuptake inhibitors
|
| gptkbp:is_studied_for |
effects on anxiety disorders
effects on mood disorders potential use in fibromyalgia potential use in neuropathic pain |
| gptkbp:is_used_in |
chronic pain management
treatment of anxiety disorders treatment of major depressive disorder off-label uses |
| gptkbp:lifespan |
5 to 11 hours
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:metabolism |
CYP2 D6 enzyme
CYP3 A4 enzyme |
| gptkbp:side_effect |
dizziness
nausea insomnia constipation dry mouth |
| gptkbp:weight |
260.35 g/mol
|
| gptkbp:bfsParent |
gptkb:Desvenlafaxine
|
| gptkbp:bfsLayer |
6
|